Clinical significance of BRAF mutations in metastatic melanoma by Chang, David Z et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Clinical significance of BRAF mutations in metastatic melanoma
David Z Chang1, Katherine S Panageas2, Iman Osman3, David Polsky3, 
Klaus Busam4 and Paul B Chapman*1
Address: 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA, 2Department of Epidemiology and 
Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA, 3Ronald O. Perelman Department of Dermatology, New York 
University School of Medicine, New York, New York, USA and 4Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, 
New York, USA
Email: David Z Chang - DZChang@mdanderson.org; Katherine S Panageas - Panageak@mskcc.org; Iman Osman - Iman.Osman@med.nyu.edu; 
David Polsky - polskd01@endeavor.med.nyu.edu; Klaus Busam - busamk@mskcc.org; Paul B Chapman* - chapmanp@mskcc.org
* Corresponding author    
Metastatic melanomaBRAF mutationClinical significance
Abstract
Forty to eighty percent of melanoma tumors have activating mutations in BRAF although the clinical
importance of these mutations is not clear. We previously reported an analysis of BRAF mutations
in metastatic melanoma samples from 68 patients. In this study, we correlated patient baseline
characteristics, prognostic factors, and/or clinical outcomes with the presence of BRAF mutations.
No significant differences were observed in age, gender, location of primary melanoma, stage at the
diagnosis, and depth of primary tumor between patients with and without BRAF  mutations.
Melanomas harboring BRAF mutations were more likely to metastasize to liver (P = 0.02) and to
metastasize to multiple organs (P = 0.048). Neither time to progression to stage IV nor overall
survival were associated with BRAF mutations. In conclusion, we observed no significant differences
in clinical characteristics or outcomes between melanomas with or without BRAF mutations.
Although there was an increased frequency of liver metastasis and tendency to metastasize to
multiple organs in tumors with BRAF mutations, there was no detectable effect on survival. Future
prospective studies should include analysis of whether BRAF  mutations in melanoma tumors
correlate with an increased tendency to metastasize to liver or to multiple organs.
Introduction
The mitogen-activated protein kinase (MAPK) pathway
mediates cellular responses to growth signals and activa-
tion of this pathway has been shown to be critical in
tumor formation, particularly in melanoma [1-3].
Recently, activating BRAF  mutations were found with
high frequency in malignant melanomas, including pri-
mary tumors and cell lines [4,5]. Suppression of activating
BRAF  mutations in cultured human melanoma cells
inhibited the MAPK cascade causing growth arrest and
promoting apoptosis [6], further suggesting the potential
critical role of activating BRAF mutations in malignant
transformation in melanoma.
We have reported the analysis of BRAF mutations in a
cohort of metastatic melanoma patients [7] and noted a
mutation proportion of 44%. As expected from previous
reports, the most frequent mutation was BRAFV599E, which
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was found in 40% of samples. Since little is known about
the clinical implications of activating BRAF mutations in
melanoma tumors, we examined whether the melanoma
tumors harboring BRAF mutations in this cohort showed
different clinical or biological features compared to the
melanoma tumors without mutations.
Materials and Methods
Retrieval of Tumor Specimens and Patient Information
Cryopreserved metastatic melanoma samples from 68
patients were selected from the Memorial Sloan-Kettering
Cancer Center Tumor Bank. Patient demographic data
were collected on the 68 patients whose tumors we had
previously analyzed for BRAF  mutations [7]. Data col-
lected included: location of primary tumor, thickness,
ulceration, stage of disease (according to American Joint
Committee on Cancer Staging System), sites of metastasis,
site of tumor biopsy, and history of and responsiveness to
chemotherapy. This retrospective analysis was performed
with IRB approval which determined that this was exempt
research under 45 CFR 46.101.b(4).
BRAF Mutations Detection
BRAF  (exons 11 and 15) was sequenced as previously
reported [7]. For 65/68 patients, a single metastatic site
was sequenced for BRAF. In three patients, two to four
metastatic sites were available for sequencing. For patients
with multiple specimens, we considered only the first
acquisition of tissue in assigning patients to mutant or
wild type categories.
Clinical Correlation and Statistical Analysis
The patients were first seen at MSKCC between June 1993
and April 2000. Clinical follow up was available through
April, 2003. Comparisons between mutated and wild type
were made using either the χ2 test, t-test or Cochran-
Armitage test to trend. Survival distributions were esti-
mated using the Kaplan-Meier method and compared
using the log-rank test. Stage IV patients were stratified
into two categories: those with stage M1a or M1b (lymph
nodes, soft tissues and/or lung metastasis) and those with
stage M1c (all other sites).
Table 1: BRAF mutations and clinical characteristics
Clinical Features BRAF Status P value
Mutation N = 30 (44.1%) Wild Type N = 38 (55.9%)
Gender
Female 11 15 0.81
Male 19 23
Age1
Mean 63.3 57.3 0.12
Median (range) 56.5 (29–91) 65.0 (42–97)
Stage at Diagnosis
I 5 3 0.92
II 13 19
III 7 10
IV 4 2
Unknown 1 4
Thickness (Number available) (N = 18) (N = 22)
Mean 2.98 4.83 0.29
Median (range) 1.75 (0.2, 20) 2.80 (0.4, 35)
Primary Site
Head/Neck 1 6
Trunk 10 11
Extremities 10 14
Ocular 1 0
Mucosal 1 0
Unknown 7 7
Response2
CR 2 3
PR 0 2
NR 16 10
Response Rate 11% 33% 0.12
1 Age at time of biopsy used to assess BRAF sequence.
2 Response data is based on the 33 patients who received systemic therapy.Journal of Translational Medicine 2004, 2:46 http://www.translational-medicine.com/content/2/1/46
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Results
We studied 74 cryopreserved metastatic melanoma sam-
ples from 68 patients: 42 men and 26 women (Table 1).
Thirty-five patients had stage III, 33 were stage IV at the
time the biopsies were obtained. These samples were
melanoma metastasis from the following sites: lung (9),
liver (3), gastrointestinal mucosa (9), soft tissues (20),
lymph nodes (31), fallopian tube and ovarian (1), and
uterus (1). Of the 68 patients analyzed, 30 had mutations
in BRAF, including one with mutations in both BRAF and
NRAS, and 38 patients were wild type. Overall, mutations
in BRAF exons 11 and 15 were detected in 30 of 68 (44%)
patients.
Patients' age ranged from 29 to 97 years; there was no sta-
tistically significant difference in patients' age with regards
to BRAF mutations (p = 0.12). Similarly, there was no dif-
ference in the distribution of primary sites and stages at
diagnosis between patients with and without BRAF muta-
tions. We noted that among the 7 melanomas arising
from the head and neck region, only 1 harbored a BRAF
mutation. Although there were too few of these patients
for a meaningful statistical analysis, this observation is
consistent with a recent report indicating that mucosal
melanomas did not harbor BRAF mutations [8,9]. The
mean thickness of primary tumor was 2.98 mm (range:
0.2, 20 mm) for patients with BRAF mutations, and 4.83
mm (range: 0.4, 35 mm) for patients without (p = 0.29).
The effect of BRAF mutation on other known prognostic
features of primary tumor such as the presence or absence
of ulceration, regression, tumor-infiltrating lymphocytes,
lymph-vascular invasion, and mitotic index could not be
assessed because this information was available for only a
small proportion of patients.
Patients with tumors harboring BRAF  mutations were
more likely to have metastasis to liver compared to those
without the mutations (41% and 13%, respectively; p =
0.02) (Table 2). Tumors with BRAF mutations were also
more likely to metastasize to multiple organs (p = 0.048)
(Table 3). Among the 51 patients who developed stage IV
disease (either at the time of the biopsy or during subse-
quent follow up), 19 out of the 27 patients (70.4%) with
BRAF mutations in their melanomas were found to have
more than one metastatic site compared to only 11 of the
24 patients (37.5%) with wild type BRAF.
We examined the response to systemic therapy (chemo-
therapy or biochemotherapy) for the 33 patients who
received such treatments. For patients with BRAF muta-
tions, 18 patients received systemic therapy of who two
patients achieved complete remission (response rate
11.1%). Fifteen patients with wild-type BRAF received sys-
temic therapy of whom three patients achieved complete
remission and two achieved partial remission (response
rate 33.3%) (p = 0.12).
Table 2: Correlation between BRAF mutations and number of metastasis among patients with stage IV melanoma
Sites of Metastasis BRAF Status P value
Mutation N = 27 (%) Wild Type N = 24 (%)
Soft Tissue/Lymph Nodes/Lung only 8 (30%) 12 (50%) 0.16
Non-soft tissue site 19 (70%) 12 (50%) 0.14
Liver 11 (41%) 3 (13%) 0.02
Table 3: Association of BRAF mutations with the number of metastatic sites in patients with stage IV melanoma
Number of Sites Per Patients BRAF Status P value*
Mutation N = 27 (%) Wild Type N = 24 (%)
5 4 (14.8%) 0 p = 0.048
4 4 (14.8%) 3 (12.5%)
3 6 (22.2%) 5 (20.8%)
2 5 (18.5%) 3 (12.5%)
1 8 (29.6%) 13 (54.2%)
* Cochran-Armitage test for trendJournal of Translational Medicine 2004, 2:46 http://www.translational-medicine.com/content/2/1/46
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There was no statistically significant difference between
time to progression to stage IV disease either from the
time of diagnosis or from stage III in patients with or with-
out BRAF mutations (data not shown). As this is a retro-
spective study, we cannot rule out the possibility that
differences in interval assessments affected our ability to
detect a difference in time to progression. On the other
hand, date of death is an endpoint not affected by interval
assessment times. There was no statistically significant
difference between patients with BRAF  mutations and
those without BRAF mutations.
Discussions
High frequency of BRAF mutations has been reported in
malignant melanoma [4,5,7], however, there has been lit-
tle clinical correlation data elucidating the biological
effects of these mutations in patients. We initiated this
study in an attempt to address this question.
The observation that BRAF  mutations are common in
melanocytic nevi [10] has led to the assumption that
mutations in BRAF occur early in melanocytic transforma-
tion and play an important role in the initiation of malig-
nant transformation. Recently, an alternative view has
been suggested by Dong et al who confirmed the high fre-
quency of BRAF mutations present both in nevi and later
stage melanomas but found few BRAF mutations in early
stage radial growth phase melanomas [11]. They interpret
these findings to mean that BRAF  mutations are not
involved in the initiation of the majority of melanoma,
but rather play a role later in progression.
Since little information was available on the biological
effects of activating BRAF  mutations in melanoma, we
analyzed the clinical characteristics of 68 melanoma
patients whose tumors we had previously analyzed for
BRAF [7]. We found that patients with tumors harboring
a BRAF mutation were more likely to have metastasis to
the liver and tended to have more organs involved with
melanoma than patients without mutations. This is con-
sistent with the idea that activating BRAF mutations affect
the pattern of metastatic spread in melanoma, although
we await confirmation of these findings in a prospective
study.
In our cohort of subjects, there were 33 patients who
received systemic therapy (18 patients with BRAF muta-
tions, 15 patients without detectable mutations). There
was a trend towards lower response rates among patients
with mutations, although this trend was not statistically
significant and is confounded by the small number of
patients, the heterogeneity of treatments these patients
received, and the retrospective nature of these analyses.
This is a question that deserves to be revisited in a pro-
spective manner.
Kumar and colleagues found that melanoma patients with
BRAF mutations showed a statistically significant dimin-
ished duration of response to treatment compared to
those without the mutations [12,13]. Their retrospective
analysis consisted of 38 patients with metastatic
melanoma (stage III or IV) who had been treated with
chemoimmunotherapy (dacarbazine, vincristine, bleo-
mycin, lomustine, and human leukocyte interferon). This
cohort of patients had a surprisingly high response rate of
55%. Although the likelihood of response did not corre-
late with the presence of a BRAF mutation, multivariate
analysis revealed that among patients who had
responded, patients with BRAF mutations had a shorter
duration of response compared to patients without any
BRAF mutations (median 3.4 versus 9.8 months). They
did not analyze the effect of BRAF mutations on the site of
metastatic spread or other biological characteristics of the
tumor.
Houben et al. reported that the presence of BRAF muta-
tion in a metastatic melanoma lesion was associated with
a poor prognosis as measured by shortened survival [14].
In our study, we did not detect any impact on either pro-
gression free or overall survival by the presence of BRAF
mutation. The patient characteristics were not reported by
Houben and colleagues but they indicate that most
patients had soft-tissue metastases (M1a or M1b). In con-
trast, most of our patients had M1c melanoma and this
could account for the different findings.
In three patients, multiple metastatic samples were avail-
able for analysis; in 2 of these patients, there was discord-
ance in the presence of detectable BRAF mutations. In one
patient in whom 2 lung metastasis collected over a period
of one month were analyzed, one metastasis contained a
BRAFV599E mutation; the other metastasis was wild-type
for BRAF. In another patient, metastasis from lung, gas-
trointestinal (GI) tract, lymph node, and soft tissue were
collected of a period of 34 months. All tumors harbored
the BRAFV599E mutation except for the GI metastasis which
was wild-type. It is possible that this discordance repre-
sents a problem with assay sensitivity, but we cannot rule
out the possibility that there is true heterogenicity among
metastasis with regard to BRAF mutations. Although this
discordance among metastasis seems to contradict the
observation that BRAF mutations are an early event in
melanocytic nevi transformation, one possibility is that in
melanomas arising from non-nevus melanocytes, BRAF
mutation is a late event occurring in individual metastasis.
Consistent with this, Shinozaki et al. recently reported
that the incidence of BRAF  mutation of primary
melanoma did not correlate with Breslow thickness, and
there was significantly higher frequency of BRAF mutation
in metastasis than in primary melanoma, arguing that
BRAF mutation maybe acquired during development ofPublish with BioMed Central    and   every 
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metastasis [15]. Houben also reported that in 3/22 cases,
the BRAF mutational status of the primary and metastasis
did not correlate [14]. This issue merits further
investigation.
In summary, this analysis represents the largest study to
date correlating BRAF mutations and clinical outcomes in
metastatic melanoma. Although we observed a statisti-
cally significant higher frequency of liver metastasis and
tendency to metastasize to multiple organs in patients
with BRAF mutations, there was no significant effect on
survival or response to systemic therapy detected by this
study. Although this analysis is limited by its retrospective
nature and the relatively small number of patients, it
appears unlikely from these observations that there will
be a major qualitative difference in the biological behav-
ior between melanomas with and without BRAF muta-
tions. Larger prospective studies are required to verify
these observations and to clarify other biological conse-
quences of BRAF mutations in melanoma.
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